Elicera Therapeutics AB has received approval from the Swedish Medical Products Agency to start a phase I/II study of chimeric antibody receptor (CAR) T-cell therapy ELC-301 in patients with refractory or relapsed B-cell lymphoma.
Researchers from Sun Yat-Sen University and MD Anderson Cancer Center have compared the proteins secreted by hepatocellular carcinoma (HCC) cells in responders and nonresponders to the anti-PD-1 antibody nivolumab.
Acepodia Inc. has obtained FDA clearance of its IND application for ACE-2016, an allogeneic γδ2 T-cell therapy for the treatment of epidermal growth factor receptor (EGFR)-expressing malignancies in patients with solid tumors.
Amphiphile (AMP)-modification of peptide antigens and molecular adjuvants has been previously demonstrated to enhance lymphatic delivery and retention, resulting in potent expansion of cognate endogenous T-cell responses.
23andme Holding Co. has received FDA clearance of its IND application for 23ME-01473 (‘1473), a dual mechanism antibody and natural killer (NK) cell activator intended to treat cancer.
Applying chimeric antigen receptor (CAR) T-cell therapy to T-cell malignancies presents important limitations due to immune suppression caused by T-cell depletion, in addition to CAR T self-killing and CAR T transfection of malignant cells.
Domain Therapeutics SA has been awarded a grant as part of the Hospital-University Research in Health (RHU) SPRINT consortium, which seeks to progress a precision medicine for cutaneous T-cell lymphoma (CTCL).
Trioar Inc. has synthesized antibody-drug conjugates comprising antibodies targeting HER2 (Neu, erbB2) covalently linked to cytotoxic drugs (particularly, MMAE and MMAF) through a linker reported to be useful for the treatment of cancer.
Doma Biopharmaceutical (Suzhou) Co. Ltd. has disclosed antibody-drug conjugates comprising bispecific antibodies (E-6C4-M-2F11) targeting EGFR (HER1; erbB1) and hepatocyte growth factor receptors (HGFR; MET) covalently linked to cytotoxic drugs through a linker reported to be useful for the treatment of cancer.
RSS
